Halozyme Therapeutics (HALO) PT Raised to $21 at BMO Capital

August 8, 2018 6:59 AM

BMO Capital raised its price target on Halozyme Therapeutics (NASDAQ: HALO) to $21.00 (from $19.00) while maintaining a Market Perform ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found